# HQ Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hq-pharma

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.hqdds.com
- Total disclosed funding: $31M
- Latest round: Series B (Dec 27, 2021)
- Investors on record: 3

## About

Based in Shanghai, China and established in 2016, HQ Pharma Co., Ltd., trading under the name HQ Pharma, is a pharmaceutical developer that engages in the development of global drug delivery systems (DDS). The company has established laboratories in Shanghai and Shandong, China and maintained an international presence with bases in USA, Canada, India, England and Australia.

In November 2023, HQ Pharma was converted into a joint stock company. In December 2025, China Meheco Group Co., Ltd. agreed to acquire a 70 % majority stake in HQ Pharma from Renhe Capital, China-Africa Development Fund, Befor Capital and other shareholders.

HQ Pharma engages in the development of global drug delivery systems, providing full-process R&D services including drug research, clinical trials, and regulatory submissions. Its main products include delivery platforms for small nucleic acids, peptides, and small molecule drugs.

The company generates revenue from developing drug delivery systems.

## Funding rounds

- Series B, Dec 27, 2021, $16M — Renhe Capital
- Series A, May 26, 2021 — Befor Capital
- Series A, Feb 9, 2021, $15M — 5Y Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Befor Capital (https://capitalatlas.ai/funds/befor-capital) — Series A
- Renhe Capital (https://capitalatlas.ai/funds/renhe-capital) — Series B